ZeCardio: a versatile platform for cardiovascular drug and target discovery
Dr. Javier Terriente, PhD Chief Scientific Officer, Zeclinics (Barcelona)
- dimecres, 28 novembre 18
Speaker: Dr. Javier Terriente, PhD
Chief Scientific Officer, Zeclinics (Barcelona)
ZeClinics is a Biotech Contract Research Organization (CRO) and early-phase biopharmaceutical (PHARMA) company using zebrafish for:
- Performing target validation
- Developing disease models for several indications
- Addressing the safety and efficacy of novel chemical molecules.
ZeClinics'business strength relies on high scientific expertise and top-notch research facilities, combined with strategic industrial partnerships and academic collaborations. The aim of the company is to challenge the traditional drug discovery pipeline by offering an economic, fast and robust array of
customized assays, designed to address the safety and biomedical relevance of novel molecules. Another strength is the use of genome editing technologies, such as CRISPR, for performing target validation and developing innovative disease model. In addition to the CRO activity, Zeclinics is developing different drug discovery pipelines in the cardiovascular field.